Akebia Therapeutics (AKBA) Receivables - Net (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Receivables - Net data on file, last reported at $62.5 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $62.5 million, up 1.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.5 million (up 1.62% YoY), and the FY2025 annual result was $47.0 million, up 36.85% from the prior year.
• Receivables - Net rose to $62.5 million in Q1 2026 per AKBA's latest filing, from $47.0 million in the prior quarter.
• Over five years, Receivables - Net peaked at $82.0 million in Q2 2022 and troughed at $18.7 million in Q1 2023.
• A 5-year average of $43.8 million and a median of $39.3 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net tumbled 76.13% in 2023, then surged 144.61% in 2025.
• A 5-year view of Receivables - Net shows it stood at $40.3 million in 2022, then retreated by 2.47% to $39.3 million in 2023, then slipped by 12.53% to $34.4 million in 2024, then jumped by 36.85% to $47.0 million in 2025, then jumped by 32.97% to $62.5 million in 2026.
• Business Quant data shows AKBA's Receivables - Net at $62.5 million in Q1 2026, $47.0 million in Q4 2025, and $66.2 million in Q3 2025.